Currently, a Phase 1 multicenter clinical trial is in progress, evaluating the pharmacodynamics, safety, and anti-tumor activity of the orally available small molecule HMGB1 inhibitor SB17170, in patients with metastatic solid tumors who have failed previous treatment (SB17170 clinicaltrials.gov). The gene discussed is HMGB1; the disease is neoplasm.